DE69014474D1 - Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. - Google Patents

Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.

Info

Publication number
DE69014474D1
DE69014474D1 DE69014474T DE69014474T DE69014474D1 DE 69014474 D1 DE69014474 D1 DE 69014474D1 DE 69014474 T DE69014474 T DE 69014474T DE 69014474 T DE69014474 T DE 69014474T DE 69014474 D1 DE69014474 D1 DE 69014474D1
Authority
DE
Germany
Prior art keywords
fragments
binding protein
antibodies against
tnf binding
against tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69014474T
Other languages
English (en)
Other versions
DE69014474T2 (de
Inventor
David Wallach
Harmut Engelmann
Dan Aderka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL9122989A external-priority patent/IL91229A/en
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69014474D1 publication Critical patent/DE69014474D1/de
Publication of DE69014474T2 publication Critical patent/DE69014474T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69014474T 1989-08-06 1990-08-06 Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente. Expired - Lifetime DE69014474T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL9122989A IL91229A (en) 1989-08-06 1989-08-06 Antibodies to tbp-i and pharmaceutical compositions containing them
IL94039A IL94039A (en) 1989-08-06 1990-04-06 Antibodies to tbp - 1 and their use

Publications (2)

Publication Number Publication Date
DE69014474D1 true DE69014474D1 (de) 1995-01-12
DE69014474T2 DE69014474T2 (de) 1995-04-20

Family

ID=26321966

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69014474T Expired - Lifetime DE69014474T2 (de) 1989-08-06 1990-08-06 Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.

Country Status (7)

Country Link
EP (1) EP0412486B1 (de)
AT (1) ATE114724T1 (de)
DE (1) DE69014474T2 (de)
DK (1) DK0412486T3 (de)
ES (1) ES2067604T3 (de)
GR (1) GR3014970T3 (de)
IL (1) IL94039A (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL107267A (en) * 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
CA2107340C (en) * 1991-06-19 2003-06-10 Gunther Adolf Monoclonal antibodies against human tnf-binding protein i (tnf-bp i)
DE4120213C2 (de) * 1991-06-19 2000-01-05 Boehringer Ingelheim Int Monoklonale Antikörper gegen das TNF-bindende Protein I (TNF-BP I)
US5582998A (en) * 1991-06-19 1996-12-10 Boehringer Ingelheim International Gmbh Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
IT1290018B1 (it) * 1997-03-04 1998-10-19 Vander Way Limited Immunoglobuline citotossiche da mammiferi
IL126024A0 (en) * 1998-03-19 1999-05-09 Yeda Res & Dev Modulators of the function of receptors of the tnf/ngf receptor family and other proteins
IL132105A0 (en) * 1998-12-24 2001-03-19 Yeda Res & Dev Caspase-8 interacting proteins
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
KR20040023630A (ko) 2001-06-26 2004-03-18 아브게닉스, 인크. Ｏｐｇｌ에 결합하는 항체
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20240038146A (ko) 2017-01-30 2024-03-22 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
AU2017398101A1 (en) 2017-02-07 2019-08-01 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies

Also Published As

Publication number Publication date
DE69014474T2 (de) 1995-04-20
DK0412486T3 (da) 1995-02-27
IL94039A (en) 2006-09-05
EP0412486A1 (de) 1991-02-13
ATE114724T1 (de) 1994-12-15
IL94039A0 (en) 1991-01-31
ES2067604T3 (es) 1995-04-01
GR3014970T3 (en) 1995-05-31
EP0412486B1 (de) 1994-11-30

Similar Documents

Publication Publication Date Title
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
NO894587L (no) Glassblanding for anvendelse i glasur og emalje.
ATE101517T1 (de) Pharmazeutische zusammensetzung, enthaltend loratadin, ibuprofen und pseudoephedrin.
DE3853822D1 (de) In acrylatpolymer dispergiertes flüssigkristallmaterial und dieses verwendende vorrichtungen.
DE3673190D1 (de) Polymerzusammensetzung und deren verwendung fuer die kontrollierten einfuehrung von reagens in fluessigkeiten.
IT1230178B (it) Procedimento e dispositivo per l'analisi quantitativa e differenziale in profondita' di provini solidi con l'impiego di due raggi ionici
DE3787241D1 (de) Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung.
DE3674642D1 (de) Zur modifizierung von bitumen verwendbare polymerzusammensetzungen und so modifizierte bitumenmassen.
DE3777721D1 (de) Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
DE58909630D1 (de) Photopolymerisierbares Gemisch und dieses enthaltendes photopolymerisierbares Aufzeichnungsmaterial
IT8919051A0 (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
BR8801757A (pt) Composicao em particulas
EP0312913A3 (en) Treatment of illnesses with patelet-activating-factor antagonists and method therefor
DK445187A (da) Apparat til undersoegelse af fejl i materialer, isaer i stoebegods
DE3687697D1 (de) Polymerzusammensetzung und deren verwendung.
IT1223336B (it) Composizione bituminosa e suo impiego nel settore dell'impermeabilizzazione
NO890680L (no) Fremgangsmaate og innretning for aa fraskille flate materialstykker.
NO900337L (no) Fremgangsmaate og anordning for aa overfoere utlutningsbare substanser i avfallsmateriale til gass eller utlutningsstabile forbindelser.
IT8122582A0 (it) Dosaggio delle proteine glicosilate in fluidi biologici e mezzi adatti allo scopo.
NO983220D0 (no) Sammensetninger og fremgangsmater for ö administrere Borrelia Burgdorferi-antigener
DE69130611D1 (de) Hydroxycholesterol enthaltende pharmazeutsiche zusammensetzungen und deren verwendung in medikamenten
DE69015732D1 (de) Flüssigkristallzusammensetzung und dieselbe enthaltende Vorrichtung.
NO892190D0 (no) Kompositt-materialer og deres anvendelse.
DE3576815D1 (de) Di(meth)akrylester und harzzusammensetzung.
BR8405580A (pt) Linhagens de celulas hibridas que produzem anticorpos monoclonicos dirigidos contra o treponema e sua utilizacao no imuno-diagnostico das infeccoes por treponema

Legal Events

Date Code Title Description
8364 No opposition during term of opposition